# Il-Yang Pharm. Co., Ltd. clinical trials: 34 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials with Il-Yang Pharm. Co., Ltd. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Il-Yang Pharm. Co., Ltd.: 34 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/il-yang-pharm-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 13, 2026 | NCT07870759 | Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia | Il-Yang Pharm. Co., Ltd. | Phase 3 | Not yet recruiting | Benign Prostatic Hyperplasia | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870759) |
| February 25, 2026 | NCT07433556 | Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers | Il-Yang Pharm. Co., Ltd. | Phase 1 | Recruiting | Healhty | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07433556) |
| January 7, 2026 | NCT07322991 | Study to Evaluate the Drug-drug Interaction Between IY001 and IY002 in Healthy Adult Male Subjects. | Il-Yang Pharm. Co., Ltd. | Phase 1 | Completed | Healthy Adult Male | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07322991) |
| December 10, 2024 | NCT06725992 | Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-NS250 and IY-NT-SR | Il-Yang Pharm. Co., Ltd. | Phase 1 | Completed | Pharmacokinetics, Pharmacodynamics | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06725992) |
| October 30, 2024 | NCT06665412 | Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML | Il-Yang Pharm. Co., Ltd. | Observational | Active not recruiting | Chronic Phase Ph+ Chronic Myeloid Leukemia | 169 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06665412) |
| June 24, 2024 | NCT06471868 | Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-HCR21 and IY-MIC | Il-Yang Pharm. Co., Ltd. | Phase 1 | Unknown | Pharmacokinetics | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06471868) |
| June 14, 2024 | NCT06461078 | Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib | Il-Yang Pharm. Co., Ltd. | Phase 1 | Completed | Drug Kinetics | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06461078) |
| February 29, 2024 | NCT06284876 | Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer | Il-Yang Pharm. Co., Ltd. | Phase 3 | Active not recruiting | Peptic Ulcer | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06284876) |
| November 15, 2022 | NCT05617651 | Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T | Il-Yang Pharm. Co., Ltd. | Phase 1 | Unknown | Pharmacokinetics | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05617651) |
| September 28, 2022 | NCT05558150 | Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac | Il-Yang Pharm. Co., Ltd. | Phase 1 | Completed | Drug Interaction Potentiation | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05558150) |
| August 22, 2022 | NCT05509543 | Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T | Il-Yang Pharm. Co., Ltd. | Phase 1 | Completed | Pharmacokinetics | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05509543) |
| February 14, 2022 | NCT05237297 | Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole | Il-Yang Pharm. Co., Ltd. | Phase 1 | Completed | Drug Interaction Potentiation | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05237297) |
| December 31, 2020 | NCT04691661 | Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease | Il-Yang Pharm. Co., Ltd. | Phase 2 | Active not recruiting | Parkinson Disease | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04691661) |
| May 11, 2020 | NCT04381689 | Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Infants | Il-Yang Pharm. Co., Ltd. | Phase 3 | Completed | Healthy | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04381689) |
| October 29, 2018 | NCT03722420 | Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) | Il-Yang Pharm. Co., Ltd. | Phase 3 | Active not recruiting | Chronic Myeloid Leukemia, Chronic Phase | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03722420) |
| March 9, 2018 | NCT03459534 | A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs | Il-Yang Pharm. Co., Ltd. | Phase 3 | Recruiting | Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome | 173 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03459534) |
| February 26, 2018 | NCT03445468 | Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents | Il-Yang Pharm. Co., Ltd. | Phase 3 | Completed | Influenza, Human | 379 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03445468) |
| February 23, 2018 | NCT03444883 | Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD | Il-Yang Pharm. Co., Ltd. | Phase 3 | Completed | Non-erosive Reflux Disease | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03444883) |
| April 4, 2017 | NCT03099876 | A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients | Il-Yang Pharm. Co., Ltd. | Observational | Unknown | Helicobacter Pylori Infection | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03099876) |
| December 20, 2016 | NCT02998437 | Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole | Il-Yang Pharm. Co., Ltd. | Phase 1 | Completed | Drug Interaction Potentiation | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02998437) |
| February 9, 2016 | NCT02677493 | Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' | Il-Yang Pharm. Co., Ltd. | Phase 3 | Completed | Influenza | 1,794 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02677493) |
| December 23, 2015 | NCT02638584 | Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. | Il-Yang Pharm. Co., Ltd. | Phase 4 | Completed | Gastric Cancer | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02638584) |
| June 25, 2015 | NCT02480998 | Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults | Il-Yang Pharm. Co., Ltd. | Phase 1/2 | Completed | Influenza, Human | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02480998) |
| March 27, 2015 | NCT02401477 | Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection | Il-Yang Pharm. Co., Ltd. | Phase 4 | Completed | Helicobacter Infections | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02401477) |
| February 2, 2015 | NCT02352701 | Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori | Il-Yang Pharm. Co., Ltd. | Observational | Completed | Helicobacter Infections | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02352701) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 1/2 | 2 |
| Phase 2 | 1 |
| Phase 3 | 13 |
| Phase 4 | 2 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Active not recruiting | 4 |
| Unknown | 3 |
| Recruiting | 2 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Influenza, Human | 8 |
| Leukemia, Myeloid, Chronic-Phase | 3 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 |
| Leukemia | 2 |
| Leukemia, Myeloid | 2 |
| Philadelphia Chromosome | 2 |
| Hematologic Diseases | 2 |
| Peptic Ulcer | 2 |
| Helicobacter Infections | 2 |
| Gastroesophageal Reflux | 1 |
| Stomach Neoplasms | 1 |
| Non-Erosive Reflux Disease | 1 |
| Parkinson Disease | 1 |
| Prostatic Hyperplasia | 1 |
| Bone Marrow Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Peruvian restaurants in the United States](https://specstream.ai/data/businesses/peruvian-restaurants/united-states)
- [Hydraulic repair companies in the United States](https://specstream.ai/data/businesses/hydraulic-repair-companies/united-states)
- [Damage restoration companies in the United States](https://specstream.ai/data/businesses/damage-restoration-companies/united-states)
- [Armenian restaurants in the United States](https://specstream.ai/data/businesses/armenian-restaurants/united-states)
- [Septic services in the United States](https://specstream.ai/data/businesses/septic-services/united-states)
- [Medical service organizations in the United States](https://specstream.ai/data/businesses/medical-service-organizations/united-states)
